IRIS
CIANI, ORIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.980
NA - Nord America 6.310
AS - Asia 4.049
SA - Sud America 559
AF - Africa 75
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 21
Totale 18.020
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.970
IT - Italia 2.983
CN - Cina 1.380
SG - Singapore 1.146
IE - Irlanda 1.112
GB - Regno Unito 552
BR - Brasile 459
UA - Ucraina 425
DE - Germania 406
HK - Hong Kong 377
RU - Federazione Russa 362
CA - Canada 270
VN - Vietnam 247
SE - Svezia 245
FI - Finlandia 242
TR - Turchia 217
KR - Corea 156
FR - Francia 143
NL - Olanda 106
IN - India 104
ID - Indonesia 72
IL - Israele 70
PL - Polonia 59
BG - Bulgaria 57
MX - Messico 57
CZ - Repubblica Ceca 54
KZ - Kazakistan 49
ES - Italia 39
JP - Giappone 38
BE - Belgio 37
AR - Argentina 31
BD - Bangladesh 29
AT - Austria 27
IR - Iran 25
ZA - Sudafrica 25
AU - Australia 22
EC - Ecuador 22
RO - Romania 22
PK - Pakistan 21
IQ - Iraq 20
CH - Svizzera 18
AE - Emirati Arabi Uniti 17
EU - Europa 17
LT - Lituania 16
MA - Marocco 15
PT - Portogallo 14
DK - Danimarca 12
VE - Venezuela 12
CL - Cile 10
CO - Colombia 9
AZ - Azerbaigian 8
LV - Lettonia 8
NO - Norvegia 8
PE - Perù 8
PH - Filippine 8
SA - Arabia Saudita 8
UZ - Uzbekistan 8
EG - Egitto 7
HU - Ungheria 7
KE - Kenya 6
KG - Kirghizistan 6
TN - Tunisia 6
GR - Grecia 5
LA - Repubblica Popolare Democratica del Laos 5
TH - Thailandia 5
LU - Lussemburgo 4
OM - Oman 4
SN - Senegal 4
TW - Taiwan 4
AD - Andorra 3
BY - Bielorussia 3
JO - Giordania 3
LK - Sri Lanka 3
NG - Nigeria 3
NP - Nepal 3
PA - Panama 3
PY - Paraguay 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
AM - Armenia 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
ET - Etiopia 2
GE - Georgia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
CD - Congo 1
Totale 18.002
Salva come PNG Salva come JPEG
Città #
Dublin 1.108
Ashburn 754
Chandler 673
Milan 661
Singapore 556
Hefei 553
Dallas 454
Hong Kong 374
Jacksonville 335
Beijing 310
Ann Arbor 258
Rome 220
Southend 215
New York 209
Toronto 194
Los Angeles 178
The Dalles 152
Redmond 149
Seoul 149
Dearborn 146
Helsinki 141
Dong Ket 130
Houston 128
Wilmington 116
Boston 101
Lawrence 97
Modena 94
Boardman 86
Munich 80
Izmir 70
Moscow 69
Buffalo 68
Jakarta 68
Naples 66
Tel Aviv 65
São Paulo 56
Frankfurt am Main 54
Redwood City 50
Almaty 49
Seattle 49
Mountain View 48
Palombara Sabina 47
Warsaw 42
Lappeenranta 40
Woodbridge 40
Bologna 36
Fairfield 36
Tokyo 34
Bari 31
Florence 31
Ho Chi Minh City 31
Brussels 30
Chennai 30
Mexico City 29
Nuremberg 29
Poplar 29
San Francisco 29
Hanoi 28
Montreal 28
Fremont 27
Genoa 27
Santa Clara 27
Stockholm 27
Turin 27
Washington 26
Brooklyn 25
London 25
Denver 24
Ottawa 23
Chicago 22
Catania 21
Council Bluffs 21
Atlanta 20
Brno 20
Johannesburg 20
Amsterdam 19
Orem 19
Assago 18
Ankara 17
Belo Horizonte 17
Bucharest 16
Kunming 16
Nanjing 16
Düsseldorf 15
Falkenstein 15
Guangzhou 15
Vienna 15
West Jordan 15
Trieste 14
Verona 14
Brescia 13
Jinan 13
Palermo 13
Phoenix 13
Rio de Janeiro 13
Robbiate 12
Secaucus 12
Turku 12
Monza 11
Napoli 11
Totale 10.679
Salva come PNG Salva come JPEG
Nome #
Esiti di salute e performance del Servizio Sanitario Nazionale 391
La funzione di HTA nelle aziende sanitarie italiane: un potenziale ancora inutilizzato? 380
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci 359
Dinamiche economiche e performance del settore dei dispositivi medici in Italia 296
EQ-5D-5L population norms for Italy 294
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani 291
I dispositivi medici in Italia: un settore, tanti mercati 281
Programma nazionale HTA per dispositivi medici: quali sfide per l’implementazione? 249
Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis 240
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making 232
Gli esiti di salute del Servizio Sanitario Nazionale 223
Surrogate endpoints: a key concept in clinical epidemiology 208
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration 206
La dimensione del settore dei dispositivi medici 205
Endpoint surrogati e politiche sanitarie: l’importanza di metodi di validazione adeguati 200
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 195
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies 194
Myth #5: health care is rightly left to the private sector, for the sake of efficiency 193
Gli esiti di salute del Servizio Sanitario Nazionale 192
Current and Future Trends in the HTA of Medical Devices 190
Real-world data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis 190
An economic perspective on urinary tract infection: the "costs of resignation" 178
Integrating HTA principles into procurement of medical devices: the Italian national HTA programme for medical devices 172
Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses 164
Surrogate endpoints in health technology assessment: an international review of methodological guidelines 163
Distinguishing features in the assessment of mHealth apps 163
An electronic patient-reported outcome mobile app for data collection in type a hemophilia: design and usability study 162
A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement 161
A scoping review of core outcome sets and their 'mapping' onto real-world data using prostate cancer as a case study 158
I processi di valutazione dei dispositivi medici e delle tecnologie sanitarie 157
Valutare l’impatto dell’HTA come strumento di governo dell’innovazione tecnologica: modelli teorici e studi empirici 155
Cost–effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma 154
The Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer 154
Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer 150
Measuring value in health care: a comparative analysis of value-based frameworks 149
A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis 148
Hospital-based HTA: quale valore per la valutazione delle tecnologie nelle Aziende Sanitarie italiane? 146
Coverage with evidence development for medical devices in Europe: can practice meet theory? 144
Comparing drug and non-drug technologies in comparative effectiveness research 143
European diabetes research and its funding, 2002–2013 142
Broadening the concept of value: a scoping review on the option value of medical technologies 142
Core outcome set in surgical oncology: why, what and how to measure 141
Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments 139
Harnessing digital health technologies during and after the COVID-19 pandemic: context matters 138
Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis 138
Mapping payment and pricing schemes for health innovation: protocol of a scoping literature review 138
A more evidence based approach to the use of surrogate end points in policy making 136
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges 135
Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy. 134
Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal 134
Mud-bath therapy in addition to usual care in bilateral knee osteoarthritis: economic evaluation alongside a randomized controlled trial 132
Exercise training for chronic heart failure (ExTraMATCH II): why all data are not equal 132
Esiti di salute e performance del Servizio Sanitario Nazionale 132
Time to review the role of surrogate end points in health policy: state of the art and the way forward 130
Non-communicable diseases: mapping research funding organisations, funding mechanisms and research practices in Italy and Germany 130
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese 129
Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials 128
La gestione dell'innovazione tecnologica in sanità: analisi e confronto di alcune politiche regionali in Italia 127
Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems? 127
Introduction to economic evaluation and health technology assessment 126
The evaluation of medical devices: are we getting closer to solve the puzzle? A review of recent trends 125
Strumenti a supporto del processo decisionale condiviso in oncologia 123
The rise of rules: will the new regulation of medical devices make us safer? 122
Esiti di salute e performance del Servizio Sanitario Nazionale 121
Value-based healthcare: il nuovo approccio di AIFA alla determinazione multidimensionale del valore 121
Assessment of nonfatal myocardial infarction as a surrogate for all-cause and cardiovascular mortality in treatment or prevention of coronary artery disease: a meta-analysis of randomized clinical trials 119
A repeated cross-sectional analysis on the economic impact of SARS-CoV-2 pandemic at the hospital level in Italy 118
Valorizzare gli esiti riferiti dal paziente : opportunità e sfide 115
Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study 115
The Coronavirus pandemic and inequality in Italy 114
Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence 114
Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study 114
Health technology assessment methods guidelines for medical devices: how can we address the gaps? the international federation of medical and biological engineering perspective 114
Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study 113
Validation of exercise capacity as a surrogate endpoint in exercise-based rehabilitation for heart failure: a meta-analysis of randomized controlled trials 113
Esiti di salute e performance del Servizio Sanitario Nazionale 112
Determinants of demand for total hip and and knee arthroplasty: a systematic literature review 112
Decision uncertainty and value of further research: a case-study in fenestrated endovascular aneurysm repair for complex abdominal aortic aneurysms 111
The impacts of diabetes research from 31 European Countries in 2002 to 2013 110
Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers 109
Response to COVID-19: was Italy (un)prepared? 109
Corona-regionalism? Differences in regional responses to COVID-19 in Italy 109
Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework 108
Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps 107
Validation of surrogate end points for overall survival in advanced colorectal cancer: a harmonized approach is needed 105
Health technology assessment of medical devices: a survey of non-European union agencies 104
Urinary Tract Infections – An Economic Issue 103
Surrogate, friend or foe? The need for case studies of the use of surrogate outcomes in cost-effectiveness analyses 102
Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer 102
Quantitative body movement and gesture assessment in ergonomics. 101
The impact of surgical experience in VATS lobectomy on conversion and patient quality of life: results from a comprehensive national video-assisted thoracic surgical database 96
A call for better reporting of trials using surrogate primary endpoints 95
Linking the regulatory and reimbursement processes for medical devices: the need for integrated assessments 95
Value lies in the eye of the patients: the why, what, and how of patient-reported outcomes measures 95
An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations 94
Design and features of pricing and payment schemes for health technologies: a scoping review and a proposal for a flexible need-driven classification 94
The role of health technology assessment bodies in shaping drug development 94
Exercise training for chronic heart failure (ExTraMATCH II): protocol for an individual participant data meta-analysis 94
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? 92
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials 90
Totale 15.144
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.258
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.258
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021923 0 0 0 0 0 91 129 58 156 118 116 255
2021/20221.500 107 220 50 68 140 66 58 233 72 145 143 198
2022/20233.178 202 173 86 266 203 223 83 162 1.398 121 161 100
2023/20242.436 109 142 149 59 258 287 193 324 98 180 303 334
2024/20253.372 108 71 228 172 179 195 276 245 961 384 341 212
2025/20264.105 758 986 365 850 1.023 123 0 0 0 0 0 0
Totale 18.470